Citations

Clear

13 citation(s) found for "Chang, Daniel".

Liver Metastasis–Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients
Lee, Grace , Oladeru, Oluwadamilola T. , Niemierko, Andrzej , Haddock, Michael G. , Toesca, Diego A.S. , Koong, Amanda Jeanette , Owen, Dawn , Weekes, Colin D. , Hong, Theodore S. , Chang, Daniel T. , Hallemeier, Christopher L. , Wo, Jennifer Y. , Gergelis, Kimberly R. , Oladeru, Oluwadamilola T , Kim, Daniel W. , Hallemeier, Christopher Leigh

Mayo Clinic

Pancreas | May 21, 2021 | Volume: 50 | Issue: 5 | Pages: 736-743

10.1097/mpa.0000000000001822 | PMID 34016893 Get It

Objectives We evaluated the outcomes of metastatic pancreatic cancer (MPC) patients who underwent liver metastases (LMs)–directed ablative radiotherapy (RT) and sought to characterize patients with more favorable prognosis. Methods A retrospective analysis of 76 MPC patients who underwent ablative RT (median dose, 50 Gy) to LM at 3 academic centers between 2008 and 2018 was performed. Endpoints were local control (LC), progression-free survival, and overall survival (OS) since RT. Results Median follow-up was 10.9 months. Liver metastases were metachronous in 68%. Before RT, LM was responsive/stable on chemotherapy (CTX) in 36% whereas progressive in 43%. Median carbohydrate antigen 19-9 (CA 19-9) at RT was 334 U/mL. After RT, 32% had ≥6 months of CTX break. Twelve-month outcomes were: LC, 66%; progression-free survival, 7%; and OS, 38%. On multivariable analysis, Eastern Cooperative Oncology Group 2–3 (hazard ratio [HR], 13.49; P < 0.01), progressive LM on CTX (HR, 3.26; P < 0.01), and higher CA 19-9 (log 10 scale; HR, 1.39; P < 0.01) at RT predicted worse OS. Conclusions Ablative RT to LM in setting of MPC may offer LC of systemic disease and thus quality time off CTX. Selected patients with good performance status, stable/responsive LM on CTX, and lower CA 19-9 have more favorable prognosis.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310

10.6004/jnccn.2019.0019 | PMID 30959462 Get It

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines
Chang, Albert J. , McBride, Sean M. , Keyes, Mira , Chung, Hans T. , Cox, Brett, Demanes, D. Jeffrey, Hsu, I.-Chow, Krauss, Daniel , Orio, Peter F. , Roach, Mack , Venkat, Puja , Vigneault, Éric , McBride, Sean, Davis, Brian J. , Cox, Brett W, Crook, Juanita , Demanes, David J, Kamrava, Mitchell, Krauss, Daniel J, Morton, Gerard , Orio Iii, Peter F, Roach Iii, Mack, Venkat, Puja S, Zeléfsky, Michael J. , Kamrava, Mitchell R.

Mayo Clinic

Journal of Clinical Oncology | September 13, 2018 | Volume: 36 | Issue: 33 | Pages: 3342-3344

10.1200/jco.18.00626 | PMID 30212298 Get It